Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Clinically speaking, Roche/Genentech’s injectable Lucentis (ranibizumab) looks well-positioned for a role in diabetic macular edema after the full release of Phase III trial data.
You may also be interested in...
Avastin, Lucentis Assumed Comparable In DME Absent More Data, MEDCAC Members Say
In a vote, the panel expressed little confidence in the adequacy of the available evidence on whether there are clinically meaningful differences in outcomes among the anti-VEGF agents.
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.